As the center of anti-tumor action in immunotherapies, PD-L1 expression represented by immunohistochemistry (IHC), whose interpretation typically focuses on the ratio of tumor cells (TC) with membranous staining, serves as a key biomarker in predicting the efficacy of ICIs. This evidence concerns the gene CD274 and neoplasm.